期刊文献+

来氟米特治疗皮质激素减量困难的寻常型天疱疮临床研究 被引量:3

Therapeutic effects of leflunomide on pemphigus vulgariswith difficulty in reducing corticosteriods
下载PDF
导出
摘要 目的:探讨来氟米特在皮质激素减量困难的寻常型天疱疮治疗过程中的作用及安全性.方法:给30例皮质激素减量困难的寻常型天疱疮患者加用来氟米特口服.结果:30例患者均顺利减量,病情明显缓解或完全缓解,16~20周后均以小剂量来氟米特维持;观察期间,所有患者均无出现明显不良反应.结论:来氟米特有助于寻常型天疱疮皮质激素治疗过程中的顺利减量,且比较安全. Objective :To explore the role and safety of leflunomide on pemphigus vulgaris with difficulty in reducting corticosteroids. Methods:leflunomide was added to 30 cases of pemphigus vulgaris reducting corticsteroids. Results:30 cases all succeeded in reduction ,and patients' condition was obviously or completely relieved. Low dose of leflunomide was maintained after 16-20 weeks. During the period of observation, no patients had obvious adverse reactions. Conclusion: Leflunomide was sate in successful reduction of corticosteroids in the treatment of pemphigus vulgaris.
出处 《陕西医学杂志》 CAS 北大核心 2006年第6期661-662,共2页 Shaanxi Medical Journal
关键词 @来氟米特 肾上腺皮质激素类 天疱疮/药物疗法 Leflunomide Adrenal cortex hormones Pemphigus/drug therapy
  • 相关文献

参考文献9

  • 1Nousari HC,Anhalt GJ.Bullous pemphigoid treated with leflunomide:a novel immunomodulatory agent.Arch Dermatol,2000;136 (10):1204
  • 2张旗,杨西瑞,张磊,荆雪.来氟米特治疗银屑病关节炎11例疗效观察[J].山东医药,2005,45(4):22-22. 被引量:1
  • 3Hamilton LC,Vojnovic I,Warner TD.A771726,the activemetabolite of leflunomide,drectly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.Br J Pharmacol,1999;127(7):1589
  • 4Alldred A,Emery P.Leflunomide:a novel D MARD for the treatment of rheumatoid arthritis.Expert Opin Pharmacother,2001;2 (1):125
  • 5Jankovic V,Samardzic T,Stosic Grujicic S,et al.Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide.Cell Immunol,2000;199(2):73
  • 6Kraan MC,de Koster BM,Elferink JG,et al.Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis:findings in a prospective,randomized,double-blind clinical trial in fifteen patients.Arthritis Rheum,2000;43(7):1488
  • 7Herrmann ML,Schleyerbach R,Kirschbaum BJ.Leflunomide:an immun-omodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.Immunophar macology,2000;47(2~3):273
  • 8Mizushima Y,Amano Y,Kitagawa H,et al.Oral administration of leflunomide (H WA486)results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model.J Pharmacol Exp Ther,1999;288(2):849
  • 9Xiao F,Lv SF,Xu SY,et al.Leflunomide a new disease-modifying drugs for treating active rheumatoid arthritis in Phase Ⅱ methotrexatecontrolled clinical trial.Chinese Medcine,2001;in press.

同被引文献35

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部